

ISSUE @ A GLANCE



Frontiers in lipid research: lipoprotein(a), apolipoprotein C-III and E, and PCSK9 and inflammation
T.F. Lüscher

2741

CardioPulse

EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials

L. Wallentin, C.P. Gale, A. Maggioni, I. Bardin, and B. Casadei

2745

The assessment of asymptomatic inherited QT prolongation for high-hazard occupations

N. Guettler, K. Rajappan, D.A. Holdsworth, and E.D. Nicol

2750

SUNecho 2019

T.-J. John, A. Pecoraro, A. Doubell, N. Masani, and P. Herbst

2754

A treadmill workstation for reading echocardiograms

K.M. Harris, D. Witt, A. Kalra, R. Bae, D. Jay, M. Newell, L. Stanberry, M. Tung, and T. Knickelbine

2756

The Story of Amiodarone

H. Tavolinejad, D. Soltani, A. Zargaran, H. Rezaeizadeh, and A. Vasheghani-Farahani

2758

CLINICAL RESEARCH

Lipids

High lipoprotein(a) and high risk of mortality

A. Langsted, P.R. Kamstrup, and B.G. Nordestgaard

2760

Editorial

Lp(a) and cardiovascular disease—Has the phoenix finally risen from the ashes?

O. Najam and K.K. Ray

2771

FAST TRACK CLINICAL RESEARCH


Lipids

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment


L.C.A. Stiekema, E.S.G. Stroes, S.L. Verweij, H. Kassahun, J. Chen, S.M. Wasserman, M.S. Sabatine, V. Mani, and Z.A. Fayad

2775

A LDL-C



B Lp(a)



Editorial

Lipoprotein (a), arterial inflammation, and PCSK9 inhibition

J.-C. Tardif, E. Rhéaume, D. Rhainds, and M.-P. Dubé

2782

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

V.J. Alexander, S. Xia, E. Hurh, S.G. Hughes, L. O'Dea, R.S. Geary, J.L. Witztum, and S. Tsimikas

2785


Editorial

- Targeting RNA to lower triglycerides: long strides from short molecules**
A. Qamar, P. Libby, and D.L. Bhatt

2797

- Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial**
H.D. White, G. Steg, M. Szarek, D.L. Bhatt, V.A. Bittner, R. Diaz, J.M. Edelberg, A. Erglis, S.G. Goodman, C. Hanotin, R.A. Harrington, J.W. Jukema, R.D. Lopes, K.W. Mahaffey, A. Moryusef, R. Pordy, M.T. Roe, P. Sritara, P. Tricoci, A.M. Zeiher, and G.G. Schwartz; for the ODYSSEY OUTCOMES Investigators

2801



Editorial

- Should myocardial infarction type 2 be regarded as two separate entities?**
K. Thygesen and A.S. Jaffe

2810

CLINICAL RESEARCH

- Prevention and epidemiology**
Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort
K.L. Rasmussen, A. Tybjaerg-Hansen, B.G. Nordestgaard, and R. Frikke-Schmidt

2813

CURRENT OPINION

Lipids

- Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine**
U. Laufs, R. Dent, P.J. Kostenuik, P.P. Toth, A.L. Catapano, and M.J. Chapman

2825

CARDIOVASCULAR FLASHLIGHTS

- Sarcoma of the pulmonary artery mimicking pulmonary artery embolism**
S. Kostic, S. Guth, G. Bachmann, C.W. Hamm, and R. Klingenberg
- Giant multiple xanthomas in familial hypercholesterolaemia**
S. Matsui, T. Maruhashi, Y. Kihara, and Y. Higashi

2824

2831

CORRIGENDA

- Corrigendum to: Standardized classification and framework for reporting, interpreting, and analyzing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC)**

2774

- Corrigendum to: Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis**

2784

Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org